Thanks to collaborations with Cerner, amassing of proprietary data and other achievements, the trial solutions firm has hit a significant access milestone.
As the COVID-19 vaccines continue the early stages of circulation in the US, the agency keeps an eye on industry actions and offers advice to key players.
Two leaders from the clinical technology solutions company discuss how digital tools like eCOAs have been invaluable in facing pandemic-related challenges.
A leader from Oracle Health Sciences examines the dynamic, challenging year and highlights creativity and ingenuity displayed by research professionals.
A representative from the global CRO outlines how forces like COVID-19, decentralized studies, globalization and others are driving change in the industry.
California information technology and services company Syntegra and the National Institutes of Health (NIH) have signed a partnership to 'democratize access to the largest set of COVID-19 patient records': with the use of Syntegra's synthetic...
The immunotherapy-focused firm reports enrollment stands at 55% for its ongoing study exploring viability of Ampion as an inhalable COVID-19 treatment.
Sosei Heptares and PharmEnable will harness artificial intelligence-enabled technology and advanced chemistry to explore neurological disease solutions.
Exploring alternative uses for drugs tapped for other indications, can save considerable time and money in discovery, according to an expert from the CRO.
The CRO is working with PWNHealth and Fulgent Genetics to enhance its monitoring program, including the addition of at-home COVID-19 testing capabilities.
The drug delivery platform company is exploring the viability of remdesivir and other potential treatments for the virus using its DehydraTECH technology.
As healthcare providers and other high-priority patients begin receiving the vaccines, the agency continues to act to help the national pandemic response.
Three leaders from pharma ingredients and innovation firm Lonza share views on challenges and opportunities likely to face the industry in coming months.
The analytical tool, developed via Bionano Genomics, maps structural variations in DNA that are known to cause disease and are tied to symptom severity.
The GoGetTested response operating system, to date used to administer more than 200,000 tests, now will scale to include health systems in more states.
A partnership between Immunai and 10x Genomics will use artificial intelligence to create a map of the immune system to help accelerate drug development.
The Medical Data Platform, an RPM solution from VivaLNK, handles clinical trials, cardiac monitoring, remote and in-patient monitoring and other tasks.
According to an executive from the drug development services company, pharma professionals should pay close attention to supply chain continuity and safety in the coming year.
A leader from the clinical trial solutions firm talks about the drive toward conducting trials without sites, and why that idea might lead to problems.
The head of the CRO’s Global Center of Excellence for Decentralized Clinical Trial Strategy outlines key developments in 2020, and keys to success in 2021.
A representative from the small-molecule solutions company explains how the ever-increasing mountain of life-sciences data has impacted drug development.
The newly formed group seeks to bring together research professionals to accelerate adoption and introduce industry standards in virtual and hybrid trials
The research (conducted by trial tech provider Litmus Health) shows an indepth picture of wearable device use, top devices, data capture and other factors.
The company’s cancer drug, devimistat, has received orphan status from the agency for treating clear-cell sarcoma, pancreatic cancer, and other diseases.
Through organizations like the Association of Clinical Research Organizations, clinical research professionals are helping decentralized research evolve.
OSP's free Digital Advances in Clinical Trial webinar (on December 9) will feature experts discussing recent advancements in the rapidly evolving field.
A leader from data-centric CRO Quanticate shares perspective on how the pandemic has disrupted trials, and what tools and technologies can keep work going.
The online DNA network has delved into self-reported data of more than 563,000 US adults to help identify genetic risk of infection and severe outcomes.
As the pandemic continues to impact the globe, the agency has kept busy issuing EUAs for potential treatments, and cited sellers of unapproved treatments.
Taking place December 9, the Digital Advances in Clinical Trials webinar covers notable advances in clinical trial technology, and the future of the field.
Health tech specialists GoodCell are working with the New York Blood Center to identify COVID-19 patients with elevated risk of adverse clinical outcomes.
A recent survey conducted by Oracle reveals trial professionals’ thoughts, feelings and behavior around decentralized research in the face of the pandemic.
The division of the National Institutes of Health has begun enrolling hospitalized patients in a trial investigating various potential COVID-19 treatments.
The company has received a $500,000 grant from the COVID-19 Therapeutics Accelerator to develop manufacturing processes for the antiviral drug remdesivir.
